Effect of advanced age and renally eliminated co-medication on plasma concentrations of Paxlovid® (nirmatrelvir-ritonavir) in patients treated for COVID-19

被引：0
|
作者：
Boeger, C. R. [1 ]
Martens-Lobenhoffer, J. [2 ]
Worthmann, H. [3 ]
Stichtenoth, D. O. [1 ]
Brod, T. [4 ]
机构：
[1] Hannover Med Sch, Inst Clin Pharmacol, Hannover, Germany
[2] Otto von Guericke Univ, Inst Clin Pharmacol, Magdeburg, Germany
[3] Hannover Med Sch, Clin Neurol & Clin Neurophysiol, Hannover, Germany
[4] Hannover Med Sch, Dept Resp Med, Hannover, Germany
来源：
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY | 2024年 / 397卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
P200
引用
收藏
页码：S66 / S66
页数：1
相关论文
共 50 条
  • [1] Nirmatrelvir-ritonavir (Paxlovid®), a treatment for Covid-19
    Buxeraud, Jacques
    Faure, Sebastien
    Fougere, Edouard
    [J]. ACTUALITES PHARMACEUTIQUES, 2020, 61 (617): : 10 - 12
  • [2] Nirmatrelvir-ritonavir for nonhospitalized patients with COVID-19
    LeBras, Marlys
    Crawley, Alex
    Legge, Marc
    Takaya, Satchan
    Lee, Stephen
    Regier, Loren
    [J]. CANADIAN FAMILY PHYSICIAN, 2023, 69 (08) : 546 - 549
  • [3] Nirmatrelvir-Ritonavir (Paxlovid) for Mild Coronavirus Disease 2019 (COVID-19) in Pregnancy and Lactation
    Lin, Christine Y.
    Cassidy, Arianna G.
    Li, Lin
    Prahl, Mary K.
    Golan, Yarden
    Gaw, Stephanie L.
    [J]. OBSTETRICS AND GYNECOLOGY, 2023, 141 (05): : 957 - 960
  • [4] Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Hospitalized Patients With COVID-19
    Focosi, Daniele
    Nicastri, Emanuele
    [J]. ANNALS OF INTERNAL MEDICINE, 2023, 176 (10)
  • [5] Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in CKD Patients With COVID-19
    Cheng, Franco Wing Tak
    Yan, Vincent Ka Chun
    Wan, Eric Yuk Fai
    Chui, Celine Sze Ling
    Lai, Francisco Tsz Tsun
    Wong, Carlos King Ho
    Li, Xue
    Zhang, Irene Ran
    Tang, Sydney Chi Wai
    Wong, Ian Chi Kei
    Chan, Esther Wai Yin
    [J]. KIDNEY INTERNATIONAL REPORTS, 2024, 9 (05): : 1244 - 1253
  • [6] Antiviral effect of azvudine and nirmatrelvir-ritonavir among hospitalized patients with COVID-19
    Gao, Yuan
    Luo, Zujin
    Ren, Shan
    Duan, Zhonghui
    Han, Ying
    Liu, Huihang
    Gao, Ziwen
    Zhang, Xinyu
    Hu, Zhongjie
    Ma, Yingmin
    [J]. JOURNAL OF INFECTION, 2023, 86 (06) : E158 - E160
  • [7] Plasma Concentrations of Paxlovid® (Nirmatrelvir/Ritonavir) in Patients with COVID-19: Results of a prospective, multi-center Observational Study
    Boeger, Corinna Regina
    Martens-Lobenhoffer, Jens
    Worthmann, Hans
    Stichtenoth, Dirk O.
    Brod, Torben
    [J]. INNERE MEDIZIN, 2024, 65 : S117 - S117
  • [8] Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Hospitalized Patients With COVID-19 Response
    Wan, Eric Yuk Fai
    Yan, Vincent Ka Chun
    Mok, Anna Hoi Ying
    Wong, Ian Chi Kei
    Chan, Esther Wai Yin
    [J]. ANNALS OF INTERNAL MEDICINE, 2023, 176 (10) : eL230265
  • [9] Nirmatrelvir-Ritonavir and COVID-19 Mortality and Hospitalization Among Patients With Vulnerability to COVID-19 Complications
    Dormuth, Colin R.
    Kim, Jason D.
    Fisher, Anat
    Piszczek, Jolanta
    Kuo, I. Fan
    [J]. JAMA NETWORK OPEN, 2023, 6 (10) : E2336678
  • [10] Real-world effectiveness and safety of nirmatrelvir-ritonavir (Paxlovid)-treated for COVID-19 patients with onset of more than 5 days: a retrospective cohort study
    Qiu, Ye
    Wen, Hao
    Wang, Haoru
    Sun, Wenjun
    Li, Guangchao
    Li, Shaoqiang
    Wang, Yan
    Zhai, Jingnan
    Zhan, Yangqing
    Su, Yutian
    Long, Zhiwei
    Li, Zhengtu
    Ye, Feng
    [J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
12345